RESEARCH TRIANGLE PARK — Liquidia Technologies, a late-stage clinical biopharmaceutical company based in Morrisville, has appointed Dr. Tushar Shah, a former executive with Teva Pharmaceuticals, to the newly created position of chief medical officer.

He will be oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for the company.

His appointment comes at a critical moment in Liquidia’s history with its pulmonary arterial hypertension treatment, LIQ861, under review; its pain relief drug LIQ865 in clinical development and a growing list of PRINT-derived preclinical candidates.

“Dr. Shah has had a long and distinguished career with nearly three decades of successful clinical development experience in high-profile therapeutic areas such as respiratory, immunology and neurology,” said Neal Fowler, Chief Executive Officer of Liquidia, in a statement.

Dr. Tushar Shah

Dr. Shah joins Liquidia from Teva Pharmaceuticals, where he served as head of Global Specialty Clinical Development with oversight of all phases of clinical development across all therapeutic areas including CNS, immunology, respiratory, oncology and biosimilars.

Prior to that, he served as senior vice president, Scientific and Clinical Development at Altana Pharma US where he built and led their clinical development function, including clinical research and operations, medical affairs, regulatory affairs and quality assurance, pharmacovigilance and drug safety, biostatistics and data management. He began his career at GlaxoSmithKline (GSK), where he held roles of increasing responsibility, rising to the position of U.S. Head, Respiratory and Inflammation, Discovery Medicine and Clinical Pharmacology with responsibility for early-stage clinical development of new therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and rhinitis.

Dr. Shah received a M.D. degree from the Hershey Medical College at Pennsylvania State University. He completed his residency in Internal Medicine at the University of North Carolina and fellowship in Allergy, Asthma and Clinical Immunology at Johns Hopkins University.

Morrisville-based Liquidia submits FDA filing for hypertension drug